Bowel Preparation — Drug-Class Hub
Bowel preparation before urinary diversion, augmentation cystoplasty, and pelvic reconstruction with bowel interposition has undergone a complete paradigm shift in the past decade. Historically extrapolated from colorectal surgery dogma, routine mechanical bowel preparation (MBP) is now omitted in 96% of published radical-cystectomy ERAS protocols[1] — supported by multiple comparative studies showing no benefit and possible harm (dehydration, frailty exacerbation, trend toward Clostridioides difficile infection). The emerging nuance is that oral antibiotic bowel preparation (OABP) may benefit continent diversions (neobladder, Indiana pouch) while providing no advantage for ileal conduits.[2][3]
This article is the drug-class pharmacology hub — PEG formulations, sodium phosphate and its boxed-warning renal liability, oral antibiotics and the Nichols protocol, and the diversion-type-dependent evidence. The clinical workflow decision table (which diversion gets which prep) lives at Postoperative constipation & ileus; use the two together.
For adjacent topics see Perioperative antibiotic prophylaxis, Post-op bowel & ileus management, and ERAS.
The Paradigm Shift — From Universal MBP to Selective Use
Five cystectomy-with-diversion studies anchor the contemporary evidence that routine MBP provides no benefit before ileal conduit:
| Study | Design | Finding |
|---|---|---|
| Shafii 2002 (n = 86) | No prep vs 4-day prep | No differences in wound infection, fistula, anastomotic dehiscence, or sepsis. Prolonged ileus lower without prep (1 vs 12 patients); LOS 22.8 vs 31.6 d[4] |
| Large 2012 (n = 180) | GoLYTELY 4 L vs no prep | No differences in UTI, dehiscence, or perioperative death. C. diff trended higher with MBP (10.5% vs 2.7%; p = 0.08)[5] |
| Raynor 2013 (n = 70) | Magnesium citrate + enema vs no prep | No differences in GI complications (22% vs 15%), bowel-function recovery, or LOS. Zero anastomotic leaks in either group[6] |
| Hashad 2012 (n = 40, RCT) | 3-day prep vs overnight fasting | No complication difference. No-prep group had less bacterial overgrowth (0% vs 25% with E. coli > 10⁵; p = 0.04) and less mucosal edema/congestion (9% vs 45%; p = 0.031) on ileal biopsies[7] |
| Aslan 2013 (n = 112, multicenter RCT) | Conventional 3-day vs limited prep | No differences; favorable trends for bowel-function recovery and LOS with limited prep[8] |
Wessels 2020 ERAS meta confirmed 96% of published radical-cystectomy ERAS protocols recommend avoiding MBP.[1] Daneshmand's widely-cited ERAS protocol is explicit: no MBP.[14]
The result: MBP before ileal-conduit diversion is now considered unnecessary and potentially harmful.
1. Polyethylene Glycol (PEG) Formulations
When MBP is used, PEG-based solutions are the preferred agents because they are isotonic, do not cause clinically significant electrolyte shifts, and are safe in the renal-impaired, cardiac-impaired, and hepatic-impaired patient populations — a meaningful advantage over sodium phosphate given the demographics of cystectomy-with-diversion candidates.[9][10]
Mechanism
PEG-3350 is an inert, non-absorbed polymer of ethylene oxide formulated with balanced electrolytes in an isotonic solution. It passes through the bowel without net absorption or secretion, producing cathartic effect through volume alone. Minimal fluid and electrolyte shifts.[9]
Formulations
| Product | Volume | Composition | Key features |
|---|---|---|---|
| GoLYTELY / CoLyte (PEG-ELS) | 4 L | PEG-3350 + sodium sulfate + NaHCO₃ + NaCl + KCl | Isotonic; gold standard; FDA-approved adults and peds ≥ 6 mo[13] |
| MoviPrep (low-volume PEG-ELS + ascorbate) | 2 L | PEG-3350 + sodium sulfate + NaCl + KCl + ascorbic acid + sodium ascorbate | Isotonic; ascorbate provides additional osmotic action; better tolerated[12] |
| PLENVU (ultra-low-volume) | 1 L | PEG-3350 + sodium sulfate anhydrous + sodium ascorbate + ascorbic acid | Lowest-volume FDA-approved PEG; isotonic |
| MiraLAX / Gatorade (off-label) | 238 g PEG-3350 in 2 L sports drink | PEG-3350 + sports-drink electrolytes | Not FDA-approved; hypotonic if used without electrolyte carrier; risk of hyponatremia, hypokalemia, hypocalcemia[10] |
Safety
- Electrolyte stability — no significant shifts in serum chemistries or CBC[9]
- Renal / cardiac / hepatic safety — considered generally safe in these populations (the key advantage vs sodium phosphate)[9]
- No mucosal histologic change[9]
- Tolerability is the main limitation — 5–15% non-completion with 4 L; low-volume formulations substantially improve compliance[9][10]
- Warnings — fluid / electrolyte abnormalities, arrhythmias, seizures, renal impairment; hydrate before / during / after; contraindicated in bowel obstruction and ileus[11][12][13]
Pediatric dosing
GoLYTELY is FDA-approved for children ≥ 6 months: 25 mL/kg/hour until stool is clear.[13]
Practical role
When MBP is used before urinary diversion — PEG (GoLYTELY 4 L or MoviPrep 2 L) is the agent of choice. For most ileal-conduit cases, MBP should simply be omitted.
2. Sodium Phosphate — Avoid in the Diversion Population
Mechanism
Hyperosmotic agent that draws water into the intestinal lumen. Low-volume cathartic effect. Produces significant fluid and electrolyte shifts — hyperphosphatemia in up to 40% of healthy patients completing a standard prep.[9]
The FDA boxed warning — acute phosphate nephropathy (APhN)
Hypovolemia-induced avid proximal salt and water reabsorption delivers a massive phosphate load to the distal nephron, causing calcium phosphate precipitation in the distal tubule and collecting duct. Time to onset is typically days but diagnosis can be delayed months. Some cases cause permanent renal impairment requiring long-term dialysis.[15][16]
Risk factors — nearly all apply to the cystectomy-diversion patient
- Older age, female sex, hypertension
- Baseline CKD
- Hypovolemia
- Bowel transit abnormalities
- Concurrent ACE inhibitors, ARBs, diuretics, or NSAIDs[15][16]
Özdemir 2025 clinicopathologic analysis — all 9 patients with biopsy-proven APhN developed CKD; one progressed to ESRD requiring dialysis.[17]
Regulatory status
OSP solution was voluntarily withdrawn from the market in 2008. OSP tablets remain available by prescription only through the REMS program.[9][15]
Practical recommendation
Sodium phosphate should be avoided before urinary diversion. The cystectomy-diversion population is precisely the risk-factor-saturated group where APhN is most likely to cause permanent harm. PEG is the default when MBP is deemed necessary.[18]
3. Oral Antibiotic Bowel Preparation (OABP)
The evidence here is colorectal-dominated and diversion-type-dependent. The historical colorectal dogma is strong; its applicability to ileal-conduit vs continent-diversion differs.
The Nichols protocol — historical backbone
Nichols 1973 introduced combining MBP with oral non-absorbable antibiotics targeting aerobic and anaerobic flora. The original 3-day protocol per current FDA labeling of neomycin and erythromycin:[19][20]
| Day | Regimen |
|---|---|
| Pre-op Day 3 | Clear liquids; bisacodyl 1 tab PO at 6 PM |
| Pre-op Day 2 | Clear liquids; MgSO₄ 15 g PO at 10 AM, 2 PM, 6 PM; enemas at 7 PM and 8 PM |
| Pre-op Day 1 | Clear liquids; MgSO₄ 15 g PO at 10 AM and 2 PM; neomycin 1 g + erythromycin base 1 g PO at 1 PM, 2 PM, and 11 PM |
| Day of surgery | Rectal evacuation at 6:30 AM for 8:00 AM surgery |
Alternative: Neomycin 1 g + metronidazole 500 mg at the same timepoints — the most common alternative when erythromycin is not tolerated, and the most-used regimen worldwide.[21]
Pharmacology of the oral antibiotics
| Agent | Class | Coverage | Key safety |
|---|---|---|---|
| Neomycin | Aminoglycoside | Aerobic gram-negative | Poorly absorbed from GI (< 3%), but systemic absorption ↑ with mucosal injury or prolonged use → nephrotoxicity, ototoxicity. Limit use to < 2 weeks.[19] |
| Erythromycin base | Macrolide | Anaerobic + gram-positive | GI intolerance (nausea / vomiting), QT prolongation, idiosyncratic reactions[20] |
| Metronidazole | Nitroimidazole | Anaerobic | Generally better tolerated than erythromycin[21] |
Colorectal evidence — strong
| Source | Finding |
|---|---|
| Willis 2023 Cochrane (16 studies, n = 3,917) | MBP + oral antibiotics ↓ SSI 137 → 77 per 1,000 (RR 0.56; 95% CI 0.42–0.74)[21] |
| Rollins 2019 meta (40 studies, n = 69,517) | MBP + oral antibiotics vs MBP alone: ↓ SSI (RR 0.51), ↓ anastomotic leak (RR 0.62), ↓ 30-d mortality (RR 0.58), ↓ ileus (RR 0.72); no CDI increase[24] |
| Vo 2018 JAMA Surg | Combined OABP + MBP ↓ SSI in left-colon / rectal resections[27] |
| ASCRS/SAGES ERAS 2023 | Strong recommendation (1B) for MBP + oral antibiotics before elective colorectal resection[25] |
| ASCRS SSI Guidelines 2024 | Strong for oral antibiotics + MBP; conditional for oral antibiotics alone when MBP contraindicated[26] |
| WHO 2016 | Oral antibiotics should be used in combination with MBP, not MBP alone[23] |
Urology-specific evidence — the nuance
The ileo-ileal anastomosis of a conduit is not a colo-colonic anastomosis. The bacterial load, anastomotic-leak risk, and procedural time differ. Contemporary urology-specific data show a diversion-type-dependent signal:
| Study | Population | Finding |
|---|---|---|
| Simhal 2025 NSQIP (n = 2,054) | Modern cystectomy cohort — 71% no bowel regimen, 21.3% MBP only, 5.3% both, 2.4% OABP only | Ileal conduit: OABP associated with ↑ LOS. Neobladder: bowel regimens not associated with worse outcomes and associated with ↓ LOS[2] |
| Simhal 2023 ASCO (n = 3,894) | OABP + continent diversion | OABP associated with ↓ sepsis and ↓ ureteral-fistula rate in continent-diversion patients. Ileal-conduit patients — OABP ↑ LOS on univariate, not after multivariable adjustment[3] |
Interpretation: the bowel anastomosis of continent reservoirs (neobladder, Indiana pouch) is more complex than an ileal-conduit anastomosis, uses larger bowel segments, and has higher stakes if leak occurs — this is the population where OABP may plausibly confer benefit. Not yet RCT-confirmed, but the signal is consistent across two NSQIP analyses.
OABP does not replace IV prophylaxis
Oral antibiotic prep is an adjunct, not a substitute. A parenteral cephalosporin (typically cefazolin ± metronidazole, or ertapenem in MRSA-risk settings per institutional antibiogram) should be given within 1 hour of skin incision regardless of oral prep use.[22][23] See Perioperative antibiotic prophylaxis.
4. Clostridioides difficile in the Urinary-Diversion Population
CDI after radical cystectomy is dramatically more common than after other urologic operations — and bowel prep choices interact with CDI risk:
| Data point | Detail |
|---|---|
| Cystectomy CDI incidence | 2.72% vs 0.19% for other urologic procedures — 14× higher[28] |
| Risk factors | Preoperative renal failure (OR 5.30); blood loss requiring transfusion (OR 1.67)[28] |
| MBP and CDI | Large 2012 — trend toward ↑ CDI with GoLYTELY MBP (10.5% vs 2.7%; p = 0.08)[5] |
| Preoperative C. diff screening | Calaway 2019 Indiana U. program — prospective screening ↓ CDI 9.4% → 5.5% (OR 0.52; p = 0.027). Positive patients placed in contact isolation and treated prophylactically with metronidazole[29] |
| Colorectal OABP and CDI | Paradoxically, OABP + MBP associated with ↓ CDI vs no prep in one propensity-matched colorectal analysis (0.5% vs 1.8%; p = 0.01); RCT meta showed non-significant trend[24][30] |
Practical implication: preoperative C. difficile screening is a low-cost, high-yield preventive intervention — halving CDI rate with contact isolation and metronidazole prophylaxis for positive screens.
5. Bowel Preparation Before Augmentation Cystoplasty
Pediatric augmentation-cystoplasty literature mirrors the adult cystectomy findings — MBP is unnecessary.
- Gundeti 2006 (n = 46 peds) — sodium picosulfate + phosphate enema MBP vs no prep before ileal cystoplasty — no significant differences in LOS (5 vs 4 d), UTI (3 vs 2), or wound infection (1 vs 1). No-prep group tolerated oral fluids earlier (24 vs 48 h) and did not require NG tubes.[31]
- Feng 2015 APSA survey — among pediatric surgeons, 31.1% use MBP alone, 26.8% diet modification only, 19.6% MBP + oral antibiotics, 12.2% no prep; greatest trend over time is abandoning MBP. Most common oral antibiotic regimen: neomycin + erythromycin (55.9%).[32]
- Laparoscopic augmentation — some surgeons still advocate limited MBP to facilitate bowel manipulation in confined working space; this is expert-opinion–based, not evidence-based.[33]
Current Evidence-Based Recommendations
| Clinical scenario | Approach | Evidence |
|---|---|---|
| Cystectomy with ileal conduit (reconstructive context) | No bowel preparation | Strong — ERAS consensus + 5 comparative studies[1][4][5][6][7][8] |
| Continent diversion (neobladder, Indiana pouch, Mainz) | Consider OABP ± MBP | Emerging — 2 NSQIP analyses; not yet RCT-confirmed[2][3] |
| Pediatric augmentation cystoplasty | No bowel preparation | Moderate — prospective comparison[31] |
| Laparoscopic / robotic cystoplasty | Consider limited MBP | Expert opinion[33] |
| Urethral / prolapse / incontinence surgery | No bowel preparation | Strong — not a bowel operation |
| Reconstruction with planned colonic resection / colonic conduit | MBP + oral antibiotics | Strong by extrapolation from colorectal literature[21][24][25] |
| Any diversion in patient with renal impairment or ACEi / ARB / NSAID use | Avoid sodium phosphate; use PEG if MBP deemed necessary | Strong — FDA boxed warning[15][16] |
Practical Summary Table
| Agent | Mechanism | Volume | Electrolyte safety | Renal safety | Tolerability | Current role |
|---|---|---|---|---|---|---|
| GoLYTELY (PEG-ELS 4 L) | Isotonic volume catharsis | 4 L | Excellent | Safe in CKD / CHF / liver disease | Poor (5–15% non-completion) | Preferred MBP agent when MBP used |
| MoviPrep (PEG 2 L + ascorbate) | PEG + ascorbate osmotic | 2 L + clears | Good | Caution in G6PD | Better than 4 L | Low-volume alternative |
| PLENVU (PEG 1 L) | Isotonic | 1 L | Good | Safe | Best | Ultra-low-volume FDA option |
| Sodium phosphate (OsmoPrep) | Hyperosmotic | Low | Poor — hyperphosphatemia / hyponatremia / hypocalcemia | ⚠️ Boxed warning — APhN / ESRD / dialysis | Good (low volume) | Generally avoided in diversion population[15][16] |
| Neomycin + erythromycin | Aerobic GN + anaerobic coverage | Oral | — | Neomycin nephrotoxicity / ototoxicity with prolonged use; erythro GI intolerance + QT | Moderate | Consider for continent diversions; Nichols timing |
| Neomycin + metronidazole | Aerobic GN + anaerobic coverage | Oral | — | Same neomycin concerns | Better than erythromycin | Most-used alternative worldwide |
Practical Pearls
- Omit MBP for cystectomy-with-ileal-conduit. 96% of ERAS protocols agree; five comparative studies show no benefit and possible harm.[1][4][5][6][7][8]
- Consider OABP before continent diversions. Two NSQIP analyses show decreased sepsis and lower LOS in neobladder / Indiana pouch patients — unlike the neutral / slightly-negative signal in ileal conduit.[2][3]
- Use PEG (GoLYTELY 4 L or MoviPrep 2 L) when MBP is used. Sodium phosphate is avoided in the diversion population because the cystectomy cohort is saturated with APhN risk factors (older age, CKD, ACEi/ARB/diuretic/NSAID use).[9][15]
- Do not use MiraLAX/Gatorade off-label for formal prep — hypotonic without sports-drink electrolytes, risk of hyponatremia / hypokalemia / hypocalcemia.[10]
- Oral antibiotics do not replace IV surgical prophylaxis. A parenteral cephalosporin within 1 h of incision is standard regardless of oral prep use. See Perioperative antibiotic prophylaxis.
- Preoperative C. difficile screening is a high-yield low-cost intervention — the Calaway program halved CDI rates from 9.4% to 5.5%.[29]
- Pediatric augmentation cystoplasty does not need MBP. Gundeti 2006 showed no benefit and earlier oral intake without prep.[31]
- Do not extrapolate colorectal evidence to ileo-ileal anastomosis. The bacterial load and anastomotic physiology differ; the OABP evidence in urology is diversion-type-dependent, not a wholesale carry-over from colorectal surgery.
- If MBP is chosen, it is a 1-day not 3-day prep. The old Nichols 3-day regimen is historical; contemporary colorectal and urologic protocols use a single-day prep + oral antibiotics where indicated.[25][26]
Related Articles
- Postoperative constipation & ileus — companion workflow article (decision framework for which diversion gets which prep)
- Post-op bowel & ileus management — alvimopan, metoclopramide, neostigmine, the rest of the postop bowel pharmacology
- Perioperative antibiotic prophylaxis — IV surgical prophylaxis (given regardless of OABP use)
- ERAS — enhanced-recovery protocol detail
- Bowel anastomosis — technical principles of GU bowel anastomosis
References
1. Wessels F, Lenhart M, Kowalewski KF, et al. "Early recovery after surgery for radical cystectomy: comprehensive assessment and meta-analysis of existing protocols." World J Urol. 2020;38(12):3139–3153. doi:10.1007/s00345-020-03133-y
2. Simhal RK, McPartland C, Wang KR, et al. "Bowel regimens before radical cystectomy: an analysis of a modern cohort." Int J Urol. 2025;32(4):402–408. doi:10.1111/iju.15668
3. Simhal R, Wang K, Poluch M, et al. "Preoperative oral antibiotic bowel preparation regimens in radical cystectomies with continent diversion." J Clin Oncol. 2023;41(Suppl 16):e16610. doi:10.1200/JCO.2023.41.16_suppl.e16610
4. Shafii M, Murphy DM, Donovan MG, Hickey DP. "Is mechanical bowel preparation necessary in patients undergoing cystectomy and urinary diversion?" BJU Int. 2002;89(9):879–881. doi:10.1046/j.1464-410x.2002.02780.x
5. Large MC, Kiriluk KJ, DeCastro GJ, et al. "The impact of mechanical bowel preparation on postoperative complications for patients undergoing cystectomy and urinary diversion." J Urol. 2012;188(5):1801–1805. doi:10.1016/j.juro.2012.07.039
6. Raynor MC, Lavien G, Nielsen M, Wallen EM, Pruthi RS. "Elimination of preoperative mechanical bowel preparation in patients undergoing cystectomy and urinary diversion." Urol Oncol. 2013;31(1):32–35. doi:10.1016/j.urolonc.2010.11.002
7. Hashad MM, Atta M, Elabbady A, et al. "Safety of no bowel preparation before ileal urinary diversion." BJU Int. 2012;110(11 Pt C):E1109–E1113. doi:10.1111/j.1464-410X.2012.11415.x
8. Aslan G, Baltaci S, Akdogan B, et al. "A prospective randomized multicenter study of Turkish Society of Urooncology comparing two different mechanical bowel preparation methods for radical cystectomy." Urol Oncol. 2013;31(5):664–670. doi:10.1016/j.urolonc.2011.03.009
9. Saltzman JR, Cash BD, Pasha SF, et al. "Bowel preparation before colonoscopy." Gastrointest Endosc. 2015;81(4):781–794. doi:10.1016/j.gie.2014.09.048
10. Jacobson BC, Anderson JC, Burke CA, et al. "Optimizing bowel preparation quality for colonoscopy: consensus recommendations by the US Multi-Society Task Force on Colorectal Cancer." Gastroenterology. 2025;168(4):798–829. doi:10.1053/j.gastro.2025.02.002
11. US Food and Drug Administration. PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride — prescribing information. Updated 2021-05-03.
12. US Food and Drug Administration. MoviPrep — prescribing information. Updated 2025-10-31.
13. US Food and Drug Administration. GoLYTELY — prescribing information. Updated 2021-05-28.
14. Daneshmand S, Ahmadi H, Schuckman AK, et al. "Enhanced recovery protocol after radical cystectomy for bladder cancer." J Urol. 2014;192(1):50–55. doi:10.1016/j.juro.2014.01.097
15. Markowitz GS, Perazella MA. "Acute phosphate nephropathy." Kidney Int. 2009;76(10):1027–1034. doi:10.1038/ki.2009.308
16. US Food and Drug Administration. Monobasic sodium phosphate and dibasic sodium phosphate — prescribing information. Updated 2024-01-30.
17. Özdemir E, Özdemir P, Yadigar S, et al. "An overlooked etiology of acute kidney injury: a clinicopathological analysis of phosphate nephropathy and review of the literature." J Clin Med. 2025;14(12):4081. doi:10.3390/jcm14124081
18. Ferguson KH, McNeil JJ, Morey AF. "Mechanical and antibiotic bowel preparation for urinary diversion surgery." J Urol. 2002;167(6):2352–2356.
19. US Food and Drug Administration. Neomycin sulfate — prescribing information. Updated 2026-02-27.
20. US Food and Drug Administration. Erythromycin — prescribing information. Updated 2024-10-17.
21. Willis MA, Toews I, Soltau SL, et al. "Preoperative combined mechanical and oral antibiotic bowel preparation for preventing complications in elective colorectal surgery." Cochrane Database Syst Rev. 2023;2:CD014909. doi:10.1002/14651858.CD014909.pub2
22. Bratzler DW, Dellinger EP, Olsen KM, et al. "Clinical practice guidelines for antimicrobial prophylaxis in surgery." Am J Health Syst Pharm. 2013;70(3):195–283. doi:10.2146/ajhp120568
23. Allegranzi B, Bischoff P, de Jonge S, et al. "New WHO recommendations on preoperative measures for surgical site infection prevention: an evidence-based global perspective." Lancet Infect Dis. 2016;16(12):e276–e287. doi:10.1016/S1473-3099(16)30398-X
24. Rollins KE, Javanmard-Emamghissi H, Acheson AG, Lobo DN. "The role of oral antibiotic preparation in elective colorectal surgery: a meta-analysis." Ann Surg. 2019;270(1):43–58. doi:10.1097/SLA.0000000000003145
25. Irani JL, Hedrick TL, Miller TE, et al. "Clinical practice guidelines for enhanced recovery after colon and rectal surgery from the American Society of Colon and Rectal Surgeons and the Society of American Gastrointestinal and Endoscopic Surgeons." Surg Endosc. 2023;37(1):5–30. doi:10.1007/s00464-022-09758-x
26. Shogan BD, Vogel JD, Davis BR, et al. "The American Society of Colon and Rectal Surgeons clinical practice guidelines for preventing surgical site infection." Dis Colon Rectum. 2024;67(11):1368–1382. doi:10.1097/DCR.0000000000003450
27. Vo E, Massarweh NN, Chai CY, et al. "Association of the addition of oral antibiotics to mechanical bowel preparation for left colon and rectal cancer resections with reduction of surgical site infections." JAMA Surg. 2018;153(2):114–121. doi:10.1001/jamasurg.2017.3827
28. Nguyen KA, Le DQ, Bui YT, et al. "Incidence, risk factors, and outcome of Clostridioides difficile infection following urological surgeries." World J Urol. 2021;39(8):2995–3003. doi:10.1007/s00345-020-03551-y
29. Calaway AC, Jacob JM, Tong Y, et al. "A prospective program to reduce the clinical incidence of Clostridium difficile colitis infection after cystectomy." J Urol. 2019;201(2):342–349. doi:10.1016/j.juro.2018.09.030
30. Poylin V, Hawkins AT, Bhama AR, et al. "The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of Clostridioides difficile infection." Dis Colon Rectum. 2021;64(6):650–668. doi:10.1097/DCR.0000000000002047
31. Gundeti MS, Godbole PP, Wilcox DT. "Is bowel preparation required before cystoplasty in children?" J Urol. 2006;176(4 Pt 1):1574–1576. doi:10.1016/j.juro.2006.06.034
32. Feng C, Sidhwa F, Anandalwar S, et al. "Contemporary practice among pediatric surgeons in the use of bowel preparation for elective colorectal surgery: a survey of the American Pediatric Surgical Association." J Pediatr Surg. 2015;50(10):1636–1640. doi:10.1016/j.jpedsurg.2015.04.005
33. Lorenzo AJ, Cerveira J, Farhat WA. "Pediatric laparoscopic ileal cystoplasty: complete intracorporeal surgical technique." Urology. 2007;69(5):977–981. doi:10.1016/j.urology.2007.02.029